glp-1 mast cell activation syndrome LDN and MCAS Central glucagon-like peptide 1 receptor
Description
Photo logging, carb and macro estimates, AI Nutritionist
Eli Lillys triple agonist demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes.
doi:10.2337/dc25-SREV
The GLP-1 Receptor Agonist market size is expected to reach $18.32 billion in 2030 at a CAGR of 5.4%, driven by rising prevalence of diabetes.
